Join
Live feed
·
PRReleasevia Quantisnow
BeyondSpring Inc. logo

BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type

ByQuantisnow·Wall Street's wire, on your screen.
BYSI· BeyondSpring Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BYSI (BeyondSpring Inc.) and more on Quantisnow.